<div><div></div><div>KALA BIO reported a year marked by a substantial operating loss and a net loss as it pivots its business model. The company recorded an operating loss of $39.161 million and a net loss of $26.980 million for the year ended December 31, 2025. Revenue and EPS were not disclosed in the extracted sections. Financial Highlights <ul><li>Operating Income: $(39.161) million (loss from operations per consolidated statement of operations)</li><li>Net Income: $(26.980) million (net loss for the year ended December 31, 2025)</li><li>Net Income Per Share: Not stated in the extracted sections</li></ul> Business Highlights <ul><li>Business pivot to AI platform: Transitioned from MSC-S biologics development to building Researgency, an on-premises AI platform targeting biotech and pharmaceutical customers.</li><li>Asset monetization strategy: Pursuing licensing and out-licensing opportunities for KPI-012, KPI-014 and legacy MSC-S intellectual property to preserve value while focusing resources on the AI strategy.</li><li>Clinical program outcome: The CHASE Phase 2b trial for KPI-012 failed to meet primary endpoints, leading to discontinuation of development of the MSC-S platform and a redirection of R&amp;D efforts.</li><li>Operational downsizing and restructuring: Executed workforce reductions, lease terminations and vendor settlements to conserve capital and realign operations toward the AI platform initiative.</li></ul>Original SEC Filing: KALA BIO, Inc. [ KALA ] - 10-K - Apr. 15, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

KALA

KALA BIO reported a significant operating loss of $39.16 million and a net loss of $26.98 million for the year ending December 31, 2025. The company is shifting its focus from MSC-S biologics to an AI platform named Researgency, targeting biotech and pharmaceutical clients. Following the failure of the CHASE Phase 2b trial for KPI-012, KALA BIO is restructuring its operations, including workforce reductions and asset monetization strategies, to align with its new AI initiative.

TradingView

KALA BIO

iShares Biotechnology ETF

iShares Global Healthcare

SPDR S&P Biotech

VanEck Biotech ETF

VG Health

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

KALA BIO 10-K: Operating loss $39.16M; Net loss $26.98M